U.S. Needle-Free Injection Market Accelerates with Breakthroughs in Vaccines, Biologics, and Pain Management

PharmaJet, Portal Instruments, and Zogenix Drive Regulatory Wins, Funding Milestones, and Clinical Progress

The U.S. needle-free injection market is entering a new growth phase, marked by landmark regulatory clearances, record funding, and strong clinical adoption signals across vaccines, biologics, and pain management.

Download Latest Sample of This Strategic Report (Use Corporate Email ID For Preference) @ https://www.datamintelligence.com/download-sample/needle-free-injection-market?ophp

PharmaJet: In August 2025, PharmaJet secured FDA clearance for its next-generation Stratis® needle-free injection system for intramuscular vaccine delivery. The system eliminates traditional needles, cutting sharps waste, boosting patient compliance, and enhancing sustainable immunization campaigns.

Portal Instruments: In July 2025, Portal Instruments raised $110 million to advance its digital jet injector platform. The device, offering real-time dosing feedback, is set to revolutionize biologics delivery by improving accuracy and enabling advanced patient monitoring in outpatient and specialty care.

Zogenix: In June 2025, Zogenix launched a pilot program with leading U.S. hospitals for its high-pressure needle-free platform targeting pain management. Early trial results highlight improved absorption, faster patient recovery, and promising adoption potential in acute and chronic care.

With patient safety, healthcare worker protection, and treatment accessibility at the forefront, the U.S. needle-free injection sector is set to redefine how therapies are administered across multiple specialties.

The needle-free injection market is primarily driven by increasing demand for pain-free and anxiety-reducing drug delivery options, especially among pediatric and geriatric populations. Rising prevalence of chronic diseases such as diabetes, which require frequent injections, is propelling the adoption of needle-free technologies to improve patient compliance and reduce complications associated with needle use. Additionally, global vaccination programs are accelerating the deployment of needle-free injectors, which minimize sharps waste and the risk of needlestick injuries among healthcare workers. The market is also benefiting from advances in technology, such as digital and high-pressure jet injectors that provide precise, real-time dosing feedback.

According to recent forecasts, the market is expected to grow at a CAGR of approximately 15.2% from 2024 to 2032, potentially reaching a valuation of over USD 300 million by 2032, up from around USD 98.5 million in 2024. North America dominates with the largest market share due to higher healthcare expenditure and early adoption of innovative injection systems, while rapid growth rates are observed in emerging regions like Asia Pacific, driven by increasing healthcare access and government immunization initiatives.

The needle-free injection market is led by jet injectors, which account for over 60% of revenue due to their broad use in vaccine and biologics delivery. Spring-based injectors also hold a significant share, favored for home care and outpatient use. Vaccine delivery dominates the application segment with about 55% share, driven by mass immunization programs, followed by chronic disease management like insulin at 30%. Hospitals and clinics represent the largest end-user category with approximately 50% market share, benefiting from institutional adoption.

The needle-free injection market is currently dominated by the North American region, holding the largest market share globally, estimated at around 40% to 43% in 2024. This leadership position is attributed to the region's advanced healthcare infrastructure, high healthcare expenditure, and proactive adoption of innovative drug delivery technologies.

The presence of key industry players, supportive regulatory frameworks, such as the FDA's encouragement of safer injection practices, and strong government initiatives to reduce needlestick injuries further reinforce North America's dominance. Additionally, significant investments in research, development, and commercialization of needle-free injection systems contribute to the widespread acceptance of these technologies across hospitals, outpatient clinics, and home healthcare settings in the region. This makes North America the largest and fastest-growing market for needle-free injection devices, setting the pace for global market trends and innovations.

Needle Free Injection Companies and Competitive Landscape

The needle-free injection market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Endo International, PharmaJet, Fierce Pharma, Medical International Technology, INJEX Pharma, National Medical Products, European Pharma Group, PenJet Corporation, and Crossject among others.

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=needle-free-injection-market

Conclusion:

The needle-free injection market is entering a phase of rapid expansion, driven by patient demand for painless, safer, and more convenient drug delivery across vaccines, biologics, and chronic disease treatments. With major regulatory approvals, strong investor backing, and technological advances in spring-loaded and digital jet injectors, the United States continues to lead global adoption, closely followed by innovation in Asia and Europe. As healthcare shifts toward user-friendly, home-based, and scalable solutions, needle-free systems are set to redefine medication administration, enhance patient compliance, and reduce healthcare costs making them an essential part of modern medicine's future.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.